Page last updated: 2024-12-06
glipalamide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
glipalamide: an antidiabetic drug; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 65802 |
| CHEMBL ID | 2105149 |
| SCHEMBL ID | 1816058 |
| MeSH ID | M0055125 |
Synonyms (23)
| Synonym |
|---|
| spc-703 |
| glipalamide |
| 3-methyl-n-(4-methylphenyl)sulfonyl-3,4-dihydropyrazole-2-carboxamide |
| w7j490cuhm , |
| glipalamidum [inn-latin] |
| glipalamidum |
| glipalamida [inn-spanish] |
| 37598-94-0 |
| (+-)-5-methyl-n-(p-tolylsulfonyl)-2-pyrazoline-1-carboxamide |
| glipalamida |
| unii-w7j490cuhm |
| glipalamide [inn] |
| 4,5-dihydro-5-methyl-n-((4-methylphenyl)sulfonyl)-1h-pyrazole-1-carboxamide |
| glipalamide [who-dd] |
| (+/-)-5-methyl-n-(p-tolylsulfonyl)-2-pyrazoline-1-carboxamide |
| glipolamide |
| spc 703 |
| CHEMBL2105149 |
| SCHEMBL1816058 |
| glipolamide; spc 703 |
| Q27292439 |
| DTXSID80865876 |
| 5-methyl-n-(4-methylbenzene-1-sulfonyl)-4,5-dihydro-1h-pyrazole-1-carboxamide |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " There was no statistically significant difference in the pharmacokinetic parameters of SPC-703 after administration of two doses, 25 and 50 mg/kg of the drug." | ( Pharmacokinetics of a new hypoglycemic agent SPC-703. Angielski, S; Jakubowski, Z, ) | 0.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (85.71) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 95.83
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (95.83) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (8.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (91.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||